Abstract Submitters

Print Friendly

ACR_4483-72

Abstract Submission Policies and Procedures

2017 information coming soon

Eligibility and General Guidelines

Print Friendly

Who is Eligible to Submit?

  • Members and non-members of the ACR or ARHP are eligible to submit an abstract

What Types of Abstracts Are Eligible for Submission?

  • Abstracts describing original basic and clinical science related to the broad area of rheumatic diseases may be submitted.
  • If the abstract reports results of a clinical trial not yet approved by a regulatory agency, you will be required to identify the trial phase.
  • Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.

What Types of Abstracts Are Not Eligible for Submission?

  • An abstract is ineligible for consideration if it reports work that has been accepted for publication as a manuscript (e.g., full-length article, brief report, case report, concise communication or letter to the editor, etc.) prior to the ACR/ARHP submission deadline (to be announced)
  • The same study should not be submitted as multiple abstracts.
  • Abstracts submitted for the ARHP program may not be dually submitted to the ACR program.
  • Abstracts that appear as more than one version of a single study will be rejected.
  • Case reports are not considered appropriate and will not be reviewed.
  • Abstracts submitted for the late-breaking category cannot be submitted to another category.

Abstract Submitter/Presenter Expectations:

  • Pay a processing fee for each abstract submission. Abstract processing fees must be in U.S. funds and are non-refundable.
  • Submit each abstract to the appropriate category.
  • By submitting your abstract, you agree to present the abstract if it is selected for presentation during an oral or poster abstract presentation at the Annual Meeting in San Diego.
  • If your abstract can only be presented as a poster, please check the appropriate box during the submission process.
  • Select an appropriate category to which an abstract will be submitted based on the disease/topic that is most relevant.
  • You will not be able to make any changes to your submission after (date to be announced) . However, you will be able to access the submission portal to view your completed abstract submission and print a copy of your submission fee receipt.
    • As English is the designated language for the meeting, the presenting author is required to speak English when presenting.

ACR Call for Abstracts

Print Friendly

The ACR annual meeting program includes content related to the clinical practice and teaching of rheumatology and the basic and translational science which contribute to the understanding of disease pathogenesis, the mechanisms and efficacy of therapeutics and the delivery of health care to patients with musculoskeletal and rheumatic disease.

Submitting an ACR Abstract

Before submitting, please review the abstract submission instructions provided on this website.

Abstract Processing Fee

A $70 processing fee must accompany each ACR abstract submission. The ACR accepts electronic payment only in the form of MasterCard, Visa and American Express. Abstract processing fees must be in U.S. funds and are non-refundable – no exceptions.

SUBMISSION DEADLINE: to be announced. Please remember, you will not be able to make any changes to your submission after the deadline.

ACR Abstract Submission Categories

Print Friendly

Basic Science

1. B Cell Biology and Targets in Autoimmune Disease: B lymphocyte differentiation, B cell subsets, plasma cells, autoantigens, autoreactive B cells and tissue injury.
2. Biology and Pathology of Bone and Joint: Joint biology and biochemistry, cartilage and chondrocyte biology, basic studies of osteoarthritis, bone structure and function, bone mineral and matrix, osteoblasts and osteoclasts.
3. Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis: Cytokines, chemokines and their receptors; downstream signaling effects and biologic pathways; cell-cell recognition and adhesion molecules, cell matrix interactions, matrix characteristics and properties, lymphoid organogenesis.
4. Genetics, Genomics and Proteomics: Techniques, strategies and observations related to disease susceptibility and expression; bioinformatics and systems biology.
5. Innate Immunity and Rheumatic Disease: Dendritic cells, antigen presentation, auto-inflammatory disease pathogenesis, pattern recognition receptors and their ligands, NK cells, complement and Fc receptors.
6. Pain – Basic Aspects: Studies on pain mechanisms, animal models of pain, and pain physiology. (Combined with clinical aspects during review process.)
7. Pediatric Rheumatology – Pathogenesis and Genetics: Pathological, genetic and other laboratory-based aspects of pediatric rheumatology conditions.
8. Rheumatoid Arthritis – Animal Models: Animal models of inflammatory synovitis, mechanisms and treatment.
9. Rheumatoid Arthritis – Human Etiology and Pathogenesis: Genetics, susceptibility loci, etiology and pathogenesis.
10. Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology: Etiology and pathogenesis, including genetics, reactive arthritis and animal models.
11. Systemic Lupus Erythematosus – Animal Models: Animal models, mechanisms and treatment.
12. Systemic Lupus Erythematosus – Human Etiology and Pathogenesis: Genetics, susceptibility loci, etiology and pathogenesis.
13. Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics: Cellular and molecular mechanisms, biomarkers.
14. T Cell Biology and Targets in Autoimmune Disease: T lymphocyte antigens and subpopulations, cognate interactions, T lymphocyte activation and proliferation.

Clinical

15. Antiphospholipid Syndrome Pathophysiology, presentation and management.
16. Education: Research on curriculum design and implementation; educational research projects; and outcomes research on physician and trainee education, including associated health training.
17. Epidemiology and Public Health: Descriptive and/or analytical studies of populations.
18. Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Regional pain syndromes; local diseases of muscle, ligament and tendon; fibromyalgia.
19.  Healthcare Disparities in Rheumatology: Population-specific differences in the presentation and clinical features of rheumatologic disease among populations; differences in the response to treatment and health outcomes; differences in biomarkers and other disease measures among populations; differences in environmental and other factors in disease susceptibility; or differences in the access to healthcare and treatment and the impact of clinical course.
20. Health Services Research: Delivery of care affecting patients with rheumatic disease; health systems and healthcare economic and utilization analysis. Research presentations share scientific findings, controlled studies and other analysis of rheumatology-related data.
21. Imaging of Rheumatic Diseases: Radiography, nuclear medicine, magnetic resonance imaging (MRI), ultrasound and computed tomography (CT).
22. Infection-Related Rheumatic Disease: Musculoskeletal manifestations of infectious disease, infectious arthritis and pathogenesis.
23. Metabolic and Crystal Arthropathies: Crystal-induced arthritis, metabolic conditions, including endocrine abnormalities.
24. Miscellaneous Rheumatic and Inflammatory Diseases: Rheumatic manifestations and therapy of less common and even rare illnesses not included in other categories (e.g., RS3PE, reticulohistiocytosis, SAPHO).
25. Muscle Biology, Myositis and Myopathies: Muscle biology, inflammatory and non-inflammatory muscle disease.
26. Orthopedics, Low Back Pain and Rehabilitation: Orthopedic conditions and interventions, physical medicine techniques and outcomes, sports medicine.
27. Osteoarthritis – Clinical Aspects: Patient-oriented studies of osteoarthritis, including treatment, diagnosis and outcomes.
28. Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis: Patient-oriented studies of bone structure and integrity and its change in various disease states.
29. Pain – Clinical Aspects: Studies on pain evaluation, pain management and pain-related functional imaging. (Combined with basic aspects during review process.)
30. Pediatric Rheumatology – Clinical and Therapeutic Aspects: Clinical aspects and treatment of inflammatory and non-inflammatory pediatric conditions.
31. Quality Measures and Quality of Care: Development and use of tools to measure or quantify healthcare processes, outcomes, patient perceptions, organizational structures and/or systems relating to healthcare goals, including safety, effectiveness, patient centricity, equity and timeliness.
32. Reproductive Issues in Rheumatic Disorders: Biologic mechanisms impacting fertility, pregnancy or fetal outcomes; management of pregnancy and preconception planning in various rheumatic diseases; issues pertaining to fertility in rheumatic disease; HPV infection and vaccinations in patients with rheumatic diseases; management of medications in pregnancy; management of neonatal complications of maternal rheumatic disease.
33. Rheumatoid Arthritis – Clinical Aspects: Clinical aspects of rheumatoid arthritis. Should not contain any treatment studies.
34. Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy: Treatment of human rheumatoid arthritis, including DMARDs, NSAIDs, glucocorticoids, new potential small molecules, biologics and gene therapy approaches. Human use only.
35. Sjögren’s Syndrome: Pathophysiology, presentation and treatment.
36. Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment: Small molecule and biologic therapies of spondyloarthropathies, reactive arthritis and psoriatic arthritis.
37. Systemic Lupus Erythematosus – Clinical Aspects and Treatment: Diagnosis, clinical manifestations, outcomes and treatment, including new small molecules, biologics and gene therapy. Human lupus only.
38. Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics: Clinical aspects of these syndromes and of treatments.
39. Vasculitis: Genetics, etiology, pathogenesis, polymyalgia rheumatica, presentation and management.


ACR/ARHP Basic Research and Clinical Research Conferences Abstracts

Print Friendly

Eligibility

  • Investigators with less than six years of experience are eligible to submit an abstract to the Basic Research Conference (BRC) or Clinical Research Conference (CRC). Young investigators will be required to check a box during the submission process to indicate if they want to have their abstract considered for inclusion in either conference.
  • Abstracts must also be submitted to the ACR or ARHP general abstract program. Acceptance to the ACR program is a prerequisite for consideration by the Basic Research Conference or Clinical Research Conference, and acceptance to either conference does not remove the abstract from the ACR general program.
  • Abstracts not accepted to the Basic Research Conference or Clinical Research Conference program are still eligible for consideration in the ACR general abstract program.
  • To be considered for inclusion in either conference, submitters must indicate the appropriate submission type before entering the submission site.

BRC/CRC Abstract Submission Processing Fee

There is no additional fee to have your abstract considered for the Basic Research or Clinical Research Conferences.

SUBMISSION DEADLINE: to be announced . Please remember, you will not be able to make any changes to your submission after the deadline. However, you will be able to access the submission portal to view your completed abstract submission and print a copy of your submission fee receipt.

Basic Research Conference Criteria

Abstracts should be broadly related to cellular metabolism regulating immune cell fate and functions, within the context of rheumatic diseases; factors influencing bioenergetics and metabolic homeostasis in the inflammatory state (drawing examples from cancer, obesity and inflammatory diseases). Abstracts may be related to the dysregulation of cellular metabolism in rheumatoid arthritis and lupus; and using cellular metabolism to reveal novel targets for the treatment of autoimmune diseases.

Clinical Research Conference Criteria

Abstracts should be broadly related to the clinical and pathophysiologic complexities of systemic autoimmunity as it relates to the lungs or they may address the types of interstitial lung disease and pulmonary hypertension associated with the rheumatic diseases. Abstracts may be related to past, ongoing and future research initiatives of lung disease within the specific rheumatic diseases.

Format

Accepted abstracts to the Basic Research and Clinical Research Conferences will be presented in oral format. Accepted BRC and CRC abstract presentations will be held during the pre-meeting sessions on November 3.

ARHP Call for Abstracts

Print Friendly

The ARHP program is planned to reflect the needs and interest of healthcare professionals who share an interest in rheumatology-related issues by providing a forum to address issues of professional significance with a multidisciplinary audience. Abstracts will be peer reviewed by a subsection of the ARHP Annual Meeting Program Subcommittee according to subject categories. ARHP abstract sessions will not necessarily be scheduled by individual category.

Submitting an ARHP Abstract

Details coming soon

ARHP Abstract Processing Fee

A $40 processing fee must accompany each ARHP abstract. The ARHP accepts electronic payment only in the form of MasterCard, Visa or American Express. Abstract processing fees must be in U.S. funds and are non-refundable — no exceptions.

SUBMISSION DEADLINE: to be announced . Please remember, you will not be able to make any changes to your submission after the deadline. However, you will be able to access the submission portal to view your completed abstract submission and print a copy of your submission fee receipt.

ARHP Abstract Submission Categories

Print Friendly

40. Clinical Practice/Patient Care: Care of patients, practice management, medication monitoring/adherence and complementary and alternative strategies.
41. Education/Community Programs: Patient education, professional education, community-based programs and public health programs.
42. Epidemiology and Public Health: Descriptive and analytical studies of health status and health outcomes of populations and patient groups.
43. Healthcare Disparities in Rheumatology: Population-specific inequalities and/or differences in access to health care, treatments and/or health outcomes; population-specific differences in rheumatic diseases related to risk factors; and susceptibility for disease.
44. Health Services Research: Health care systems and delivery, economic evaluations, quality improvements and analysis.
45. Pediatrics: Pediatric practice and patient care.
46. Psychology/Social Sciences: Social, emotional and behavioral factors affecting patients, families and providers.
47. Rehabilitation Sciences: Physical therapy, occupational therapy, exercise programs, splinting/orthotics and other rehabilitation services.
48. Research Methodology: Quantitative and qualitative studies, new assessment tools and methodology, new analytical techniques and research study management.

Students, Residents and Fellows-in-Training/Annual Meeting Awards

Print Friendly

The ACR encourages submission of abstracts by presenting authors who are pre-doctoral and post-doctoral students, residents, medical students or fellows-in-training. Please check the appropriate box in the submission site to indicate your training status. You may be eligible for a Rheumatology Research Foundation Award.

Rheumatology Research Foundation Abstract Award

The Rheumatology Research Foundation offers award opportunities for medical students, residents and pediatric rheumatology fellows who submit an abstract for the ACR/ARHP Annual Meeting by the submission deadline.

  • Award recipients will receive a cash award plus reimbursement of travel expenses to attend the meeting.
  • Acceptance of an abstract does not automatically enroll or guarantee receipt of a Foundation Abstract Award.
  • Fellows must submit an abstract to the annual meeting by (date to be announced) in order to be eligible.
  • Application deadline for the Foundation’s Abstract Awards is (date to be announced)
  • Visit the Foundation’s Annual Meeting Awards website or call 404-633-3777, ext. 318 for complete award details.


Abstract Submission Instructions/Guidelines

Print Friendly

Submitting an Abstract

  • All abstracts must be submitted online.
  • Submitters will be able to access complete submission instructions and guidelines online

Abbreviations

  • Use standard abbreviations. A list of acronyms for many common rheumatology terms has been developed by an international group of rheumatology journal editors.
  • Place special or unusual abbreviations in parentheses after the first time the full word appears.
  • Do not abbreviate compounds in the title of the abstract.
  • Use numerals to indicate numbers, except when beginning sentences.

Abstract Character Limit

  • Abstract Title Character Limit: 250 characters which EXCLUDES spaces.
  • Abstract Body Character Limit: 2,750 characters which EXCLUDES the title, names of authors/coauthors, authors’ affiliations, spacing and disclosures.
  • Abstract Image, Table and/or Graphic Upload Limit: There is a limit total of 3 image, table and/or graphic uploads per submission. Each uploaded table and/or graphic will decrease the character count by 250 characters from the total limit allowed.
  • References will be included against the character count.
  • Abstracts exceeding the character limit will be considered “incomplete”.
  • Abstracts marked “incomplete” at the close of the submission deadline will be ineligible for consideration.

Abstract Title

  • Take special care when entering your title as it may be published exactly as submitted.
  • Titles should be brief, clearly indicating the nature of the presentation.
  • Title character limit is 250 characters.
  • Titles DO NOT count toward the 2,750 abstract content character limit.
  • Include only commonly used acronyms in the abstract title.
  • Do not include trial group names or trial group acronyms in the abstract title, as they are not included in the unified list of acronyms approved by the principal journal editors in the field of rheumatology.
  • Enter the title in the “title” field only and do not enter the title in the body of the abstract.
  • When entering the abstract title online, use mixed case (do not use all caps OR all lower case) and do not put a period at the end of the title:

Correct:

This Is a Properly Formatted Abstract Title

Incorrect:

THIS IS AN IMPROPERLY FORMATTED ABSTRACT TITLE

This is an improperly formatted abstract title

T his is an imp roperly formatted abstract title.

Acronym Usage

  • Abstract Title: ACR/ARHP will only publish commonly used acronyms included in the unified list of acronyms approved by the principal journal editors in the field of rheumatology.
  • Abstract Body: Acronyms may remain in the body of the abstract and in the author list. Acronyms not included in the unified list of acronyms are acceptable for inclusion in the abstract body.

Authors

  • There is no limit to the number of authors that may be included in the author block.
  • All presenting authors and co-authors must disclose any relevant financial relationship(s) at the time of abstract submission.
  • See the abstract disclosure policy and authorship criteria below for additional author identification details and instructions.

Authorship Criteria

  • Substantial contributions to study conception and design.
  • Substantial contributions to acquisition of data.
  • Substantial contributions to analysis and interpretation of data.
  • Drafting the article or revising it critically for important intellectual content.
  • Final approval of the version of the article to be published.
  • Other critical study activities (specify).
  • List authors of a trial group as “(insert first/last name of author) on behalf of (insert trial name)”.
  • There is no limit on the number of authors that may be included in the author block.
  • Complete instructions are available in the author’s section of the late-breaking abstract submission site.

Content

  • Do not use new technical words, laboratory slang, words not defined in dictionaries, or abbreviations or terminology not consistent with internationally accepted guidelines.
  • Define any abbreviations the first time they are used.
  • Refer to the unified list of acronyms for recommendations on acceptable terms for scientific communication.
  • Omit all names and geographical references in the body of the abstract.
  • Organize content as follows:

Background: Background or Statement of Purpose

Methods: Methods, materials and analytical procedure used*

Results: Summary of the results in sufficient detail to support conclusion

Conclusion: Conclusions reached (do not state “results will be discussed”)

*Please Note: In order to make the description of patients as clear as possible and to facilitate comparisons with other studies, the Methods section should include, whenever possible, a short paragraph detailing the proportion of patients who satisfy the ACR classification criteria for the particular disease described.

Image, Tables, and Graphics

  • Up to three images are allowed, however each image/table counts as 250 characters towards your maximum of 2750 total characters.
  • The characters in the table do NOT count towards this limit – each table is worth exactly 250 characters.
  • The maximum allowable size of each image is 2.5 MB.
  • Images will be accepted as PNG, JPG, or GIF files.
  • If your table exceeds eight (8) columns, please upload it as an image. This will help us ensure consistent and accurate output of your abstract at time of publication.

Disclosure Policy

  • As a CME provider accredited by the Accreditation Council for Continuing Medical Education, the American College of Rheumatology must ensure balance, independence, objectivity, and scientific rigor in all its educational activities.
  • To this end, the ACR requires that individuals (presenters/speakers, moderators, reviewers, authors and planners and their spouse/partners) disclose to the planning committee, ACR and audience any relevant financial relationships with commercial interests who have an opportunity to affect the content of CME about the products or services of that commercial interest. In the case where such relationships exist, the ACR must resolve the conflict of interests.
  • If no relationships exists individual MUST STATE that NONE exist to reflect that the question was asked and answered.
  • The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months of both the individual and/or spouse/partner (i.e., see Relevant Financial Relationships below).
    *Relevant Financial Relationships:
    1. Stock options or bond holdings in a for-profit corporation or self-directed pension plan;
    2. Research grants;
    3. Employment (full or part-time);
    4. Ownership or partnership;
    5. Consulting fees or other remuneration;
    6. Non-remunerative positions of influence, such as officer, board member, trustee or public spokesperson;
    7. Receipt of royalties;
    8. Speakers’ bureau; or
    9. Other.
    None: has no relevant financial relationship to discloseCommercial interest is considered any entity producing marketing, re-selling or distributing health care goods or services consumed by, or used on, patients.Conflict of Interest exists when individuals (within 12 months, including the spouse/partner) have a relevant financial relationship with a commercial interest and the opportunity to affect the content of the CME about the products or services of that commercial interest.

Disclosure Statement Submission

  • Keep in mind, all disclosure information must be entered in the on-line submission site – the ACR does not accept paper disclosure statement forms.
  • Presenting Authors are permitted to enter the disclosure information on the behalf of each co-author during the on-line abstract submission process.
  • To assist Presenting Authors and Co-authors in deciding what is necessary to disclose online, you may download the following ACR CME Disclosure Statement and Attestation Form.
  • Each Co-author may choose to complete this form and return it to Presenting Author.

Institutional Review Board Affirmation
An Institutional Review Board is charged with protecting the rights and welfare of people involved in research. If your research involved human subjects you will be required to check a box during the submission process to attest that you have received the appropriate IRB approval.

Multiple Submissions of Same Study

  • The same study should not be submitted as multiple abstracts.
  • Therefore, if the abstracts in question are not different enough to be considered separate studies (specifically, if they address the same research question or present the same results), they may all be rejected.

Online Revisions

  • Proofread abstracts carefully to avoid errors before they are submitted. Your abstract, if selected, will be published in print and electronic versions exactly as submitted.
  • You may return to the online abstract submission site to revise your abstract until (date to be announced) . After this date/time, the submission site will close and changes will not be made.
  • Should a submission contain errors or the omission of contributing author names after the deadline, the abstract may be withdrawn.

Presentation Formats

  • Abstracts are considered for either oral presentation or poster presentation.
  • As English is the designated language for the meeting, the presenting author is required to speak English when presenting.
  • If your abstract can only be presented as a poster, please check the appropriate box in the “Abstract Title” section of the submission site.

Product Name Usage

    • If a product has received FDA approval, the proprietary drug name may appear once in parentheses in the title only. The nonproprietary (generic/scientific) name must be used in the body of the abstract.
    • If a product has not received FDA approval, only the nonproprietary name may be used in the title and abstract body.
    • In the case of biosimilars:
      • The approved reference product for a biosimilar should be referred to by the nonproprietary name of the biopharmaceutical preceded by the term “reference” (e.g., “reference adalimumab” for Humira) in the abstract body.
      • The proprietary drug name of the reference product may appear once in parentheses in the title only.
      • If a biosimilar has not received FDA approval, only the unique nonproprietary name may be used in the title and abstract content. If no unique nonproprietary name exists for a biosimilar, the investigational drug name must be used, not the trade name.

 

Example title: “Review of Research for ABP 501, a Biosimilar Candidate for Reference Adalimumab (Humira)”

Example text reference: ABP 501 (reference adalimumab)

  • Failure to comply will result in disqualification of your submission.

Study Design Abstract Submissions

  • A study design abstract could be appropriate for submission if, like any other abstract submission, it describes a hypothesis, description of methodology, data, interpretation of data, etc. (e.g., one study design could be compared to another).
  • The category to which the abstract would be submitted should be selected based on the clinical disease for which the study design is most relevant.

Study Sponsor Statements

  • For abstracts about studies that were funded by a pharmaceutical company, biotech company or other commercial enterprise, a “Role of the Study Sponsor” statement must be included (use plural “Sponsors” if more than one sponsor is listed).
  • This statement describes for the learner the part played by the commercial entity in the conduct and reporting of the study. IMPORTANT: This applies only to commercial enterprises (e.g., pharmaceutical or biotech companies; device manufacturing companies).
  • It does not apply to government entities such as the National Institute of Health (NIH) or its equivalent funding agencies in other countries or to public or private foundations.
  • Study sponsor statements will be published in electronic version only on the ACR website.

Review and Notification

Print Friendly

Abstract Review

  • After the submission deadline, completed abstracts will be peer-reviewed.
  • Incomplete abstracts cannot be processed and will not be reviewed.
  • To ensure the integrity of the review process, revisions to abstracts will not be accepted after the submission deadline – no exceptions.
  • Abstracts will be peer-reviewed by a subsection of the ACR Abstract Selection Committee or the ARHP Annual Meeting Program Sub-committee, according to subject categories.
  • All reviewers are required to sign a confidentiality agreement.
  • All abstracts will be reviewed without knowledge of the author(s), institution(s) or disclosure information.
  • Accepted abstracts will be selected as either a short oral presentation or a poster presentation.

Abstract Notification

The ACR will notify the presenting author of the status of their abstract via e-mail. It is the presenting author’s responsibility to then notify all co-authors. The ACR graciously requests that all interested parties please refrain from directly contacting the ACR to obtain information regarding abstract status, notification distribution and/or publication dates. Please check this website regularly for the most up-to-date information.

  • PRESENTING AUTHORS MUST SUBMIT AN E-MAIL ADDRESS THEY WILL HAVE ACCESS TO AFTER THE SUBMISSION DEADLINE.
  • Presenting authors will be notified of acceptance or rejection of their abstract in late October via email.
  • The presenting author is the only author who will receive notification from the ACR.
  • Presenting authors are responsible for notifying all additional abstract co-authors.
  • IMPORTANT: The presenting author is the sole point of contact for all abstract co-authors. The ACR will direct all co-author inquiries to the presenting author.
  • The late-breaking presenting authors will be notified in late-October and are responsible for notifying all late-breaking abstract co-authors.

IMPORTANT INFORMATION REGARDING ABSTRACT PRESENTATION SCHEDULE CONFLICTS
– Abstract session and presentation schedules cannot be changed to accommodate presenting author scheduling conflicts.
– Presenting authors may appoint a co-author listed on the abstract to serve as an alternate presenter (see “Presenting Author Responsibilities” for more information).
– Invited speaker and moderator schedules cannot be changed to accommodate abstract oral or poster presentation conflicts.

Revisions/Withdrawals

Print Friendly

Revisions

  • Proofread abstracts carefully to avoid errors prior to submission.
  • Your abstract, if selected, will be published online exactly as submitted.
  • You may return to the online submission site to revise your abstract until (date to be announced)
  • After this date/time, the submission site will close and no additional changes, edits, revisions, etc. can be made – no exceptions.
  • Should a submission contain errors or the omission of contributing author names after the deadline, presenters may opt to have the abstract withdrawn.

Withdrawals

  • After October 6, presenting authors may submit a request to have an abstract withdrawn.
  • All requests can only be made by the presenting author and must be submitted via e-mail to: withdrawn@rheumatology.org.
  • Withdrawal requests must include the following:

– Abstract ID Number
– Abstract Title
– Presenting Author’s Name

  • Removal of withdrawn abstract from online supplement of Arthritis & Rheumatology cannot be guaranteed if the request is received after (date to be announced)

Presentation Guidelines

Embargo Policy

Print Friendly

Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until (date to be announced) . Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy.

For more information regarding the ACR Embargo Policy, please contact the ACR Public Relations Department.

Registration and Housing

Print Friendly

Registration and Housing

  • All presenting authors are required to register and pay the appropriate registration fees and arrange hotel accommodations.
  • Submitting an abstract or acceptance of an abstract does not register you or ensure hotel accommodations for the meeting.
  • As abstract presentation dates will be finalized in late-August, presenting authors should plan to attend the entire meeting.
  • Scheduled abstract sessions will not be changed to accommodate travel schedules.
  • Registration and housing will open for members on (date to be announced) and non-members on (date to be announced).
  • Get more registration and housing details on ACRannualmeeting.org/register.

Need Help?

Print Friendly

Submission Site Technical Assistance:

For technical assistance regarding the abstract submission site, contact The Conference Exchange technical support at 401-334-0220 or via email at acr@confex.com between 8:30 AM and 6:00 PM, ET, Monday – Friday.

General Abstract Submission Inquiries:

For general inquiries regarding abstract submission, email abstracts@rheumatology.org.

Frequently Asked Questions

Print Friendly

When is the general abstract submission deadline?
To be announced

When are the Rheumatology Research Foundation Annual Meeting Awards deadlines?
To be announced

Visit the Foundation’s Annual Meeting Awards website or call 404-633-3777, ext. 318 for complete award details.

I do not have an ACR account, how can I submit my abstract?
You do NOT need an ACR account to submit an abstract. All abstracts must be submitted via the online abstract submission website between (dates to be announced).

Do I need to be a member of the College to submit an abstract?
You do NOT have to be an ACR or ARHP member to submit an abstract. All abstract must be submitted via the online abstract submission website between (dates to be announced).

I’m not a rheumatologist; can I submit an abstract?
Yes. Non-rheumatologists may submit abstracts to the ACR and/or ARHP abstract programs.

What are the different types of annual meeting abstract programs?
ACR Call for Abstracts: The ACR annual meeting program includes content related to the clinical practice and teaching of rheumatology and the basic and translational science which contribute to the understanding of disease pathogenesis, the mechanisms and efficacy of therapeutics and the delivery of health care to patients with musculoskeletal and rheumatic disease.

ARHP Call for Abstracts: The ARHP program is planned to reflect the needs and interest of healthcare professionals who share an interest in rheumatology-related issues by providing a forum to address issues of professional significance with a multidisciplinary audience.

Basic Research Conference (BRC) or Clinical Research Conference (CRC) Calls for Abstracts: Young investigators with less than six years of experience may also submit an abstract that has been submitted to the ACR or ARHP general program to the Basic Research Conference (BRC) or Clinical Research Conference (CRC) for consideration. Accepted BRC and CRC abstract presentations will be held during the pre-meeting sessions on November 11. Acceptance to either conference does not remove the abstract from the general program. To be considered for the BRC or CRC program, you must check the appropriate submission type at the beginning of submission process to indicate if they want to have their abstract considered for inclusion in either conference.

I’m employed by a commercial interest. May I submit an abstract?
Yes. You must disclose this information in your disclosure statement during the abstract submission process. If accepted, you must also disclose this information on your abstract presentation.

Can I submit research that I have presented elsewhere?
You may submit an abstract that has been previously presented prior to (date to be announced)

*Please Note: The late-breaking abstract category allows for the submission of truly late-breaking high impact scientific research for which results were not available at the time of the general abstract submission deadline. Late-breaking abstracts should present data that is ground-breaking, innovative, newsworthy and has a high impact factor. This category is not a mechanism to allow for updated data to be submitted later when preliminary data were available by the general abstract submission deadline. More information will be available here in July.

Important Dates

Print Friendly

Coming soon

Late-Breaking Abstracts

The late-breaking abstract category allows for the submission of truly late-breaking high impact scientific research for which results were not available at the time of the general abstract submission deadline.

Late-breaking abstracts should present data that are high impact, ground breaking, innovative, and newsworthy. This category is not a mechanism to allow for updated data to be submitted later when preliminary data were available by the general abstract submission deadline.

Please read the Late-breaking Eligibility Requirements and Submission Procedures sections below carefully before submission.

Late-Breaking Eligibility Requirements

Print Friendly

What is Eligible for Late-breaking Abstract Submission? *

  • Truly late-breaking, high-impact scientific research for which results were not available at the time of the abstract submission deadline.
  • Late-breaking abstracts describing clinical trials or original and groundbreaking basic science may be submitted.
  •  * IMPORTANT:  Abstracts that do not meet these criteria will not be reviewed.

What is Not Eligible for Late-breaking Abstract Submission?

  • Abstracts submitted in the general abstract submission but not accepted should NOT be submitted to the late-breaking category.
  • An abstract is ineligible for consideration if it reports work that has been accepted for publication as a manuscript (e.g., full-length article, brief report, case report, concise communication or letter to the editor, etc.) prior to the ACR/ARHP submission deadline of noon ET on .
  • An abstract is ineligible for consideration if preliminary data were available at the time of the general abstract submission deadline.
  • The same study cannot be submitted as multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.
  • Case reports are not considered appropriate and will not be reviewed.
  • Abstracts submitted to another ACR or ARHP abstract category will not be reviewed.

In order for an abstract to be considered for late-breaking presentation, the presenting author must: *

  • Explain why this abstract could not have been submitted for the regular abstract deadline.
  • Explain in 50 words or less why the findings are of high scientific impact, especially newsworthy and deserving of consideration. Please Note: Stating that “results are only now available” is not a sufficient explanation.
  • Explain the impact of the work contained in the abstract submission in 50 words or less.
  • Identify the trial phase, if the abstract reports results of a clinical trial not yet approved by a regulatory agency.
    * IMPORTANT:  Submissions that leave any of these details unanswered will not be considered for review.

Late-Breaking Abstract Submission Policies and Procedures

Print Friendly

Submission Timeline and Fees

  • The late-breaking abstract submission website will open on (date to be announced) . Please check back on this website for the link.
  • A $130 processing fee is required for each late-breaking abstract submission. Abstract processing fees must be in U.S. funds and are non-refundable.
  • You will not be able to make any changes to your submission after the deadline . However, you will be able to access the submission portal to view your completed abstract submission and print a copy of your submission fee receipt.

Submission Instructions and Requirements

  • Members and non-members of the ACR or ARHP are eligible to submit a late-breaking abstract.
  • Go to the Abstracts page and click the abstract submission link to get started.
  • Select an appropriate category to which an abstract will be submitted based on the disease/topic that is most relevant.
  • If your abstract can only be presented as a poster, please check the appropriate box during the submission process.
  • If the abstract reports results of a clinical trial not yet approved by a regulatory agency, you will be required to identify the trial phase.
  • Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
  • By submitting your late-breaking abstract, you agree to present the abstract, if it is selected, during an oral or poster abstract presentation at the Annual Meeting in San Diego
  • As English is the designated language for the meeting, the presenting author is required to speak English when presenting.